The process of bringing a new medicine to market is lengthy, expensive and incredibly uncertain. Intellectual property protections help incentivize this investment and research, bringing new, valuable medicines to patients. See how: https://lnkd.in/eH2NeTP5
PhRMA
Pharmaceutical Manufacturing
Washington, DC 56,281 followers
Research. Progress. Hope.
About us
Our Mission: The Pharmaceutical Research & Manufacturers of America (PhRMA) has as its mission to conduct effective advocacy for public policies that encourage discovery of important new medicines for patients by pharmaceutical and biotechnology research companies. To accomplish this mission, PhRMA is dedicated to achieving these goals in Washington, the states and the world: Broad patient access to safe and effective medicines through a free market, without price controls; Strong intellectual property incentives; And transparent, effective regulation and a free flow of information to patients. Who We Are: The Pharmaceutical Research and Manufacturers of America (PhRMA) represents innovative biopharmaceutical research and discovery companies. PhRMA is devoted to advancing public policies in the U.S. and around the world that support innovative medical research, yield progress for patients today and provide hope for the treatments and cures of tomorrow. Key Facts about the Biopharmaceutical Industry: - Since 2000, PhRMA member companies have invested more than $900 billion in the search for new treatments and cures. - America’s biopharmaceutical industry is the global leader in medical innovation, with more than 500 new medicines approved by the Food and Drug Administration since 2000. - The biopharmaceutical pipeline has over 7,000 new medicines currently in development around the world. Get fresh content daily by subscribing to our updates at https://catalyst.phrma.org/subscribe
- Website
-
https://www.PhRMA.org
External link for PhRMA
- Industry
- Pharmaceutical Manufacturing
- Company size
- 201-500 employees
- Headquarters
- Washington, DC
- Type
- Nonprofit
- Founded
- 1958
- Specialties
- Policy, Scientific Research, Advocacy, Public Affairs, Federal Affairs, State Government Affairs, and pharmaceuticals
Locations
-
Primary
950 F Street, NW
Suite 300
Washington, DC 20004, US
Employees at PhRMA
Updates
-
A new FTC interim report underscores how pharmacy benefit managers (PBMs) profit at patients’ expense and drive up medicine costs. The report details how PBMs: ➡️ steer patients to pharmacies they own ➡️ control what medicines are covered and what patients pay for them ➡️ reduce competition and push out independent pharmacies ➡️ pocket rebates meant for patients
-
Americans are calling on policymakers to address harmful practices by insurers and pharmacy benefit managers (PBMs) that limit access to new medicines and treatments. A recent Morning Consult/PhRMA poll of over 20,000 Americans across all 50 states and 435 congressional districts reveals that 8 in 10 Americans are concerned that: - PBMs profit off of financial assistance that is intended to help patients afford the medicine they need, or block people from using this assistance altogether. - PBMs influence what medicines patients get and control what patients pay at the pharmacy. It's clear Americans want real solutions that hold big insurers and their PBM middlemen accountable for making it harder for patients to get the care they need. Dive into the poll's key findings below.
New 50-state poll: Americans want to hold health insurers and PBMs accountable for high out-of-pocket costs and other harmful practices
phrma.org
-
Treatments for Alzheimer’s can mean more to patients and caregivers than just slowing down the disease. They can mean more time to do things on their own and more conversations with friends, kids and grandkids. Chris Leibman, SVP, Value, Access, Public Policy and Government Affairs at Biogen, shares the value of these therapies with our COO Lori Reilly: https://lnkd.in/eyTEu8rD
-
PhRMA reposted this
In recent years, there have been major treatment advances in oncology – but, with cancer claiming millions of lives each year, there is still significant need for innovation to address the greatest needs of patients. How can we as a biopharmaceutical company protect the innovation ecosystem to support and promote discovery of novel therapies? Daniel Asch, Vice President of the Oncology Franchise weighs in on the transformative potential of cancer care at #PeopleVCancer. Watch here: https://bit.ly/4chTz4h PhRMA
-
-
The IRA’s price setting provisions could result in 3.5 million Medicare patients facing higher out-of-pocket costs in 2026 – undermining the benefits of the new out-of-pocket limit for millions of seniors and people with disabilities. More: https://lnkd.in/dvF2qJdM
-
-
Alzheimer’s disease is a devastating illness that gradually robs a person of everything they hold dear. Recently, Lori Reilly spoke with Shobha Dhadda of Eisai US about the life-changing impact new treatments could have on patients and caregivers. Watch the full conversation: https://lnkd.in/eZ-Gcx5X
-
"They are called pharmacy benefit managers. And they are driving up drug costs for millions of people, employers and the government." Below, The New York Times exposes the abusive tactics of PBMs, reporting on how they control patients’ access to meds, pocket patient savings, and drive up costs.
The Opaque Industry Secretly Inflating Prices for Prescription Drugs
https://www.nytimes.com
-
"Science is vital to getting new Alzheimer's therapies to market. But the public policy environment plays a critical role in whether those medicines actually ever do get to the patient." Watch more from Eli Lilly and Company's Anne White and PhRMA's Lori Reilly: https://lnkd.in/eJMDwRfE
-
The CBO's report that increasing Hep C treatments would save billions continues to demonstrate the long-term value of medicines. These are the same cures insurers once falsely claimed would bankrupt the system. This data speaks to a bigger story of how payers continue to share a misleading narrative about the cost of new, innovative medicines. Insurers use these scare tactics to restrict & deny coverage to patients. As we've seen with Hep C and other treatments, these claims are false. Read more about the CBO report: https://lnkd.in/ePjf3HiH And more on insurers' misleading narratives here: https://lnkd.in/ex9nWFfS
Boosting hepatitis C treatment would save money, CBO says
axios.com